The aim of the present study was to develop an experimental paradigm for the study of serotonergic neurotransmission in humans using positron emission tomography and the 5-HT2A selective radioligand [18F]altanserin. [18F]altanserin studies were conducted in seven subjects using the bolus/infusion approach designed for attaining steady state in blood and brain 2 hours after the initial [18F]altanserin administration. Three hours after commencement of radiotracer administration, 0.25 mg/kg of the selective serotonin reuptake inhibitor, citalopram (Lundbeck, Valby, Denmark), was administered to all subjects as a constant infusion for 20 minutes. To reduce 5-HT1A-mediated autoinhibition of cortical 5-HT release, four of the seven subjects were pretreated with the partial 5-HT1A agonist pindolol for 3 days at an increasing oral dose (25 mg on the day of scanning). In each subject, the baseline condition (120 to 180 minutes) was compared with the stimulated condition (195 to 300 minutes). Despite a pronounced increase in plasma prolactin and two subjects reporting hot flushes compatible with an 5-HT-induced adverse effect, cortical [18F]altanserin binding was insensitive to the citalopram challenge, even after pindolol pretreatment. The biochemical and cellular events possibly affecting the unsuccessful translation of the citalopram/pindolol challenge into a change in 5-HT2A receptor binding of [18F]altanserin are discussed.
The Danish Council of Ethics...believed that the brain-death criterion should not be accepted without public education and debate. Following the introduction of a spectrum of educational and related activites, a Gallup poll found that 98% of the survey population was aware of the debate over brain-vs-heart criteria and that 80% favoured the adoption of a supplemental brain-death standard... This raises the fundamental question of decisionmaking in pluralist democratic societies, of the limits of democratic involvement in such choices, and of the role of bodies like the Danish Council of Ethics... It must be part of the mission of a governmental bioethical body to use its peculiar expertise to teach and to lead -- to build a popular consensus out of confusion. But in doing so, such a Commission will be steering a dangerous course....
Combined PET/MRI systems are now commercially available and are expected to change the medical imaging field by providing combined anato-metabolic image information. We believe this will be of particular relevance in imaging of cancer patients. At the Department of Clinical Physiology, Nuclear Medicine & PET at Rigshospitalet in Copenhagen we installed an integrated PET/MRI in December 2011. Here, we describe our first clinical PET/MR cases and discuss some of the areas within oncology where we envision promising future application of integrated PET/MR imaging in clinical routine. Cases described include brain tumors, pediatric oncology as well as lung, abdominal and pelvic cancer. In general the cases show that PET/MRI performs well in all these types of cancer when compared to PET/CT. However, future large-scale clinical studies are needed to establish when to use PET/MRI. We envision that PET/MRI in oncology will prove to become a valuable addition to PET/CT in diagnosing, tailoring and monitoring cancer therapy in selected patient populations.
Denmark has implemented a comprehensive, nationwide pharmaceutical information system, and this system has been evaluated by the Danish Council of Ethics. The system can be seen as an exemplar of a comprehensive health information system for clinical use.
The paper analyses 1) how informed consent can be implemented in the system and how different implementations create different impacts on autonomy and control of information, and 2) arguments directed towards justifying not seeking informed consent in this context.
Based on the analysis a heuristic is provided which enables a ranking and estimation of the impact on autonomy and control of information of different options for consent to entry of data into the system and use of data from the system.The danger of routinisation of consent is identified.The Danish pharmaceutical information system raises issues in relation to autonomy and control of information, issues that will also occur in relation to other similar comprehensive health information systems. Some of these issues are well understood and their impact can be judged using the heuristic which is provided. More research is, however needed in relation to routinisation of consent.
Cites: Bioethics. 1991 Apr;5(2):105-1211652014
Cites: Soc Sci Med. 2002 Sep;55(5):709-1912190265
Cites: Ann Pharmacother. 2003 Feb;37(2):259-6712549958
Cites: J R Soc Med. 2004 Sep;97(9):415-2015340019
Cites: Int J Law Psychiatry. 1981;4(1-2):53-727327819
BACKGROUND Increasing attention is being paid to research misconduct in academic journals and in the media, but we know relatively little about its extent or attitudes to research misconduct, or how these are changing. This study therefore aims to investigate PhD candidates' knowledge, own actions and attitudes to specific forms of research misconduct.MATERIAL AND METHOD In autumn 2015, an anonymous questionnaire survey was distributed to all participants in the introductory course for PhD candidates at the Faculty of Medicine at the University of Oslo.RESULTS Altogether 77 PhD candidates (79 %) responded to the questionnaire. A total of 62 % conducted clinical research and 25 % conducted basic research. Around one in four had heard about serious forms of research misconduct in the previous year, and around 4 % were aware of various forms of serious research misconduct in their own department in the previous year. Compared to earlier studies, an increasing number (16 %) responded that they had been subjected to unethical pressure with regard to inclusion or order of authors. Approximately two-thirds were uncertain of whether their department had written policies for academic conduct. One-third of PhD candidates did not disassociate themselves from actions that are generally viewed as scientific misconduct. One-tenth thought it acceptable to falsify or fabricate data in order to expedite publication, one-fifth did not object to taking the credit for others' ideas, and almost half did not believe it was wrong to attempt a number of methods of analysis until one arrived at a significant answer.INTERPRETATION PhD candidates at the Faculty of Medicine were aware of research misconduct, both generally and from their own department. They themselves reported some type of scientific misconduct, and a large majority were uncertain of their department's guidelines. Some of the candidates also accepted several forms of research misconduct.
The knowledge of scientific dishonesty is scarce and heterogeneous. Therefore this study investigates the experiences with and the attitudes towards various forms of scientific dishonesty among PhD-students at the medical faculties of all Norwegian universities.
Anonymous questionnaire distributed to all post graduate students attending introductory PhD-courses at all medical faculties in Norway in 2010/2011. Descriptive statistics.
189 of 262 questionnaires were returned (72.1%). 65% of the respondents had not, during the last year, heard or read about researchers who committed scientific dishonesty. One respondent had experienced pressure to fabricate and to falsify data, and one had experienced pressure to plagiarize data. On average 60% of the respondents were uncertain whether their department had a written policy concerning scientific conduct. About 11% of the respondents had experienced unethical pressure concerning the order of authors during the last 12?months. 10% did not find it inappropriate to report experimental data without having conducted the experiment and 38% did not find it inappropriate to try a variety of different methods of analysis to find a statistically significant result. 13% agreed that it is acceptable to selectively omit contradictory results to expedite publication and 10% found it acceptable to falsify or fabricate data to expedite publication, if they were confident of their findings. 79% agreed that they would be willing to report misconduct to a responsible official.
Although there is less scientific dishonesty reported in Norway than in other countries, dishonesty is not unknown to doctoral students. Some forms of scientific misconduct are considered to be acceptable by a significant minority. There was little awareness of relevant policies for scientific conduct, but a high level of willingness to report misconduct.
Cites: J Clin Pathol. 2001 Jan;54(1):4-611271787
Cites: Nature. 2012 Jan 19;481(7381):237-822258568
Cites: Sci Eng Ethics. 2002 Apr;8(2):191-20512092490
Cites: J Med Ethics. 2003 Apr;29(2):97-10212672890
Cites: Acad Med. 1992 Nov;67(11):769-751418260
Cites: Science. 1993 Jan 29;259(5095):584-5, 647-88430300
Cites: Tidsskr Nor Laegeforen. 1993 Oct 20;113(25):3149-528273040
Cites: Tidsskr Nor Laegeforen. 1995 Oct 20;115(25):3148-518539699
Cites: Acad Med. 1996 Mar;71(3):267-738607927
Cites: Lancet. 1999 Jul 3;354(9172):57-6110406378
Cites: Nature. 2005 Jun 9;435(7043):737-815944677
Cites: BMJ. 2005 Jul 30;331(7511):281-816052022
Cites: Med Educ. 2006 Mar;40(3):269-7716483330
Cites: Med J Aust. 2006 Jun 19;184(12):632-516803444
Cites: J Med Ethics. 2007 Jun;33(6):365-917526690
Cites: Acad Med. 2007 Sep;82(9):838-4517726387
Cites: Acad Med. 2007 Sep;82(9):853-6017726390
Cites: Lakartidningen. 2007 Aug 8-21;104(32-33):2244-717822203